[go: up one dir, main page]

WO2025045752A1 - Récepteur de commutateur cd 95 humain chimérique, lymphocytes t exprimant un tel récepteur conjointement avec un récepteur de lymphocytes t modifié, vecteurs respectifs, kits, compositions pharmaceutiques et méthodes pour traiter un patient présentant une maladie - Google Patents

Récepteur de commutateur cd 95 humain chimérique, lymphocytes t exprimant un tel récepteur conjointement avec un récepteur de lymphocytes t modifié, vecteurs respectifs, kits, compositions pharmaceutiques et méthodes pour traiter un patient présentant une maladie Download PDF

Info

Publication number
WO2025045752A1
WO2025045752A1 PCT/EP2024/073652 EP2024073652W WO2025045752A1 WO 2025045752 A1 WO2025045752 A1 WO 2025045752A1 EP 2024073652 W EP2024073652 W EP 2024073652W WO 2025045752 A1 WO2025045752 A1 WO 2025045752A1
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
cell
polypeptide
domain
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/073652
Other languages
English (en)
Inventor
Mikhail STEKLOV
Friederike KNIPPING
Panagiota A. SOTIROPOULOU
Marleen Van Loenen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
T Knife GmbH
Original Assignee
T Knife GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T Knife GmbH filed Critical T Knife GmbH
Publication of WO2025045752A1 publication Critical patent/WO2025045752A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4231—Cytokines
    • A61K40/4232—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95

Definitions

  • the present invention relates to an isolated T-cell, wherein the T-cell expresses a chimeric CD 95 receptor comprising a polypeptide, wherein said polypeptide comprises at least one CD 95 polypeptide region having at least 60% sequence identity with a polypeptide domain, a polypeptide region or a polypeptide motif of a wildtype human CD 95 receptor, wherein said human CD 95 polypeptide region comprises a CD 95 extracellular ligand binding domain.
  • the present invention also relates to a vector comprising a nucleic acid encoding the chimeric CD 95 receptor, as well as to isolated T- cells in which the vector has been introduced.
  • the invention further relates to a kit for preparing the (isolated) T-cell of the present invention, as well as to a pharmaceutical composition comprising the T-cells.
  • the invention also relates to a method for preparing a T-cell for immunotherapy, and to methods for treating a patient having a disease comprising administering the pharmaceutical composition, and/or for increasing cytotoxicity of a T-cell in adoptive cell therapy, comprising introducing the vector into the T-cell.
  • the present invention further relates to a chimeric CD 95 receptor comprising a polypeptide, wherein said polypeptide comprises at least one CD 95 polypeptide region having at least 60% sequence identity with a polypeptide domain, a polypeptide region or a polypeptide motif of a wildtype human CD 95 receptor, wherein said human CD 95 polypeptide region comprises a CD 95 extracellular ligand binding domain, further wherein said polypeptide comprises at least one non-CD 95- co-stimulatory cytoplasmic polypeptide domain, region or motif.
  • T-cells are known to be important mediators of adaptive cell-mediated immune responses.
  • Adoptive T-cell therapy (ACT) with T-cells expressing native or transgenic ⁇ -T-cell receptors (TCRs) is a promising treatment for cancer, as TCRs cover a wide range of potential target antigens [Chandran and Klebanoff, 2019].
  • Native TCR specificities have successfully been exploited for ACT with tumor infiltrating lymphocytes (TILs) for melanoma [Dafni et al., 2019] and other tumors [Chandran and Klebanoff, 2019], or with virus-specific T-cells (VSTs) for viral-associated malignancies [Leung and Heslop, 2019]
  • Transgenic TCR-based ACT allows the genetic redirection of T-cell specificity in a highly specific and reproducible manner, and has produced promising results in melanoma and several solid tumors [Robbins et al., 2015], multiple myeloma (MM
  • T-cell antigen recognition and subsequent T-cell activation is known to depend on the interaction between the T-cell receptor (TCR) and peptide-major histocompatibility complex (pMHC) molecules [Davis and Bjdrkman, 1988],
  • TCR T-cell receptor
  • pMHC peptide-major histocompatibility complex
  • the CD8 co-receptor plays a major role in CD8 T-cell activation
  • the CD4 co-receptor stabilizes the interaction between the TCR on CD4 T-cells and the MHC class II molecule on antigen-presenting cells (APCs).
  • APCs antigen-presenting cells
  • T-cells need to receive positive signals.
  • co-signaling molecules have a crucial role in regulating T-cell activation, subset differentiation, effector function and survival.
  • CD28 is constitutively expressed on naive CD4 and CD8 T- cells and has been shown to act as positive co-stimulatory molecule.
  • CD28 engagement in the immunological synapse decreases the amount of antigen necessary to elicit T-cell activation [Kamphorst et al., 2015], [006]
  • many other costimulatory molecules have been identified.
  • TNFRSF co-signaling receptors with co-stimulatory function include HVEM (herpesvirus entry mediator), death receptor 3 (DR3; also known as TNFRSF25), CD40 (also known as TNFRSF5) and lymphotoxin- ⁇ receptor (LTBR; also known as TNFRSF3) [Chen and Flies, 2013], Furthermore, all receptors of the type-V, or divergent, family — including 4-1 BB (also known as CD137 or TNFRSF9), 0X40 (also known as TNFSF4), CD27 (also known as TNFRSF7), glucocorticoid-induced TNFR- related protein (GITR; also known as TNFRSF18) and CD30 (also known as TNFRSF8) — also function primarily as co-stimulatory molecules [Croft et al., 2012], For example, HVEM (herpesvirus entry mediator), death receptor 3 (DR3; also known as TNFRSF25), CD40 (also known as TNFR
  • TLRs Toll like receptors
  • innate immune cells particularly antigen-presenting cells
  • TLR agonists can enhance cytokine production by activated T-cells, increase T- cell sensitivity to T-cell receptor stimulation, promote long-lived T-cell memory, and reduce the suppressive activity of regulatory T-cells.
  • ACT’S targeting tumor cell specific antigen genes
  • solid tumors can effectively evade the immune response, including the promising T cell therapies, through the expression of various inhibitory molecules that can hinder the function of T cells.
  • IgSF immunoglobulin superfamily
  • TNFRSF tumor necrosis factor receptor superfamily
  • CD 95 Fes - receptor
  • CD95L also known as e.g. FASL
  • This object is inter alia accomplished by the (isolated) T-cells, the vectors, the pharmaceutical compositions, the kits, the methods, and the chimeric CD 95 receptors having the features of the respective independent claims.
  • the invention provides an isolated T-cell, wherein the T-cell expresses a chimeric CD 95 receptor comprising a polypeptide, wherein said polypeptide comprises at least one CD 95 (-derived) polypeptide region having at least 60% sequence identity with a polypeptide domain, a polypeptide region or a polypeptide motif of a human CD 95 receptor as set forth in SEQ ID No.
  • said CD 95 (-derived) polypeptide region comprises a CD 95 extracellular ligand binding domain; further wherein said polypeptide comprises at least one non-CD 95 (-derived) co-stimulatory cytoplasmic polypeptide domain, region or motif of a tumor necrosis factor receptor superfamily protein comprising CD40, CD40L, CD27, HVEM, GITR, CD30, 0X40, and/or LTBR, an immunoglobulin superfamily (IgSF) protein, a Toll-like-receptor, and/or an IL6-receptor family protein; wherein the T-cell further expresses an engineered T-cell receptor.
  • a tumor necrosis factor receptor superfamily protein comprising CD40, CD40L, CD27, HVEM, GITR, CD30, 0X40, and/or LTBR, an immunoglobulin superfamily (IgSF) protein, a Toll-like-receptor, and/or an IL6-receptor family protein
  • the invention provides an isolated T-cell, wherein the T- cell expresses a chimeric CD 95 receptor comprising a polypeptide, wherein said polypeptide comprises at least one CD 95 (-derived) polypeptide region comprising a CD 95 extracellular ligand binding domain; further wherein said polypeptide comprises at least one non-CD 95 (-derived) co-stimulatory cytoplasmic polypeptide domain, region or motif of a tumor necrosis factor receptor superfamily protein comprising CD40, CD40L, CD27, HVEM, GITR, CD30, 0X40, and/or LTBR, an immunoglobulin superfamily (IgSF) protein, a Toll-like-receptor, and/or an IL6-receptor family protein; wherein the T-cell further expresses an engineered T-cell receptor.
  • a tumor necrosis factor receptor superfamily protein comprising CD40, CD40L, CD27, HVEM, GITR, CD30, 0X40, and/or LT
  • the inventors have found that the T-cells comprising both an engineered T- cell receptor and a chimeric CD 95 receptor including the costimulatory domain of CD40, CD40L, CD27, HVEM, GITR, CD30, 0X40, and/or LTBR, an immunoglobulin superfamily (IgSF) protein, a Toll-like-receptor, and/or an IL6-receptor family protein, thus being engineered for use as a switch receptor, is able to turn negative signals e.g. present in a tumor microenvironment into positive signals for T-cell activation.
  • IgSF immunoglobulin superfamily
  • the T- cells as herein provided by expressing both an engineered T-cell receptor and specifically engineered recombinant chimeric CD 95 receptors, linking the co-stimulatory domains as herein described to at least one CD 95-derived polypeptide region that is still capable to bind to its natural ligand, is having resistance to the immunosuppressive tumor microenvironment.
  • the T-cells exhibit less TCR-T exhaustion and depletion through apoptosis, and show stimulated TCR-T proliferation and functional activity.
  • the expression ..region of a tumor necrosis factor receptor superfamily protein as referred to herein may relate to a protein portion that preserves the ability to propagate co-stimulatory signal transduction of a functional costimulatory tumor necrosis factor receptor superfamily protein analogous to a wildtype tumor necrosis factor receptor superfamily protein.
  • the expression undertakenmotif of a tumor necrosis factor receptor superfamily protein as referred to herein may relate to a protein portion being a recognizable region of protein structure that may be defined by a unique chemical or biological function, and which also preserves the ability to propagate co-stimulatory signal transduction of a functional costimulatory tumor necrosis factor receptor superfamily protein analogous to a wildtype tumor necrosis factor receptor superfamily protein.
  • the T-cells as herein provided comprise chimeric CD 95 switch receptors which lack the cytoplasmic inhibitory motif/domain/region of the wildtype CD 95 receptor, the binding of CD95L to the CD 95 switch receptor, e.g. in tumor microenvironment, does no longer lead to e.g. inhibition of activation, promotion of exhaustion and/or induction of apoptosis of the T-cell expressing the chimeric CD 95 switch receptor, but - instead - even costimulates the T-cell, thereby enhancing its cytotoxic effect.
  • the invention provides a vector comprising a nucleic acid comprising a nuclear acid sequence encoding for a chimeric CD 95 receptor comprising a polypeptide, wherein said polypeptide comprises at least one CD 95 (-derived) polypeptide region having at least 60% sequence identity with a polypeptide domain, a polypeptide region or a polypeptide motif of a human CD 95 receptor as set forth in SEQ ID No.
  • said human CD 95 polypeptide region comprises a CD 95 extracellular ligand binding domain; further wherein said polypeptide comprises at least one non-CD 95 (- derived) co-stimulatory cytoplasmic polypeptide domain, region or motif of a tumor necrosis factor receptor superfamily protein comprising CD40, CD40L, CD27, HVEM, GITR, CD30, 0X40, and/or LTBR, an immunoglobulin superfamily (IgSF) protein, a Toll- like-receptor, and/or an IL6-receptor family protein; and further comprising a nucleic acid comprising a nuclear acid sequence encoding for an engineered T-cell receptor.
  • a tumor necrosis factor receptor superfamily protein comprising CD40, CD40L, CD27, HVEM, GITR, CD30, 0X40, and/or LTBR, an immunoglobulin superfamily (IgSF) protein, a Toll- like-receptor, and/or an IL6-
  • the invention provides a vector comprising a nucleic acid comprising a nuclear acid sequence encoding for a chimeric CD 95 receptor comprising a polypeptide, wherein said polypeptide comprises at least one CD 95 (-derived) polypeptide region comprising a CD 95 extracellular ligand binding domain; further wherein said polypeptide comprises at least one non-CD 95 (-derived) co-stimulatory cytoplasmic polypeptide domain, region or motif of a tumor necrosis factor receptor superfamily protein comprising CD40, CD40L, CD27, HVEM, GITR, CD30, 0X40, and/or LTBR, an immunoglobulin superfamily (IgSF) protein, a Toll-like-receptor, and/or an IL6-receptor family protein; and further comprising a nucleic acid comprising a nuclear acid sequence encoding for an engineered T-cell receptor.
  • a tumor necrosis factor receptor superfamily protein comprising CD40, CD40L, CD27, HVEM
  • the vector in addition to comprising the nucleic acid sequence encoding for the chimeric CD 95 receptor and the nucleic acid sequence encoding for the engineered T-cell receptor, the vector may further comprise a nucleic acid encoding for a CD8 Co-receptor, such as a wildtype CD8 Co-receptor or a chimeric CD8 Co-receptor.
  • a CD8 Co-receptor such as a wildtype CD8 Co-receptor or a chimeric CD8 Co-receptor.
  • overexpression of a chimeric human CD 95 receptor as herein described in the T-cells as herein provided alongside an engineered transgenic ⁇ -T-cell receptor TCR and, in some embodiments, for example, alongside a CD8 Co-receptor, may offer several advantages and expands the therapeutic potential of this approach.
  • the optional, additional provision of the CD8 Co-receptor together with the chimeric CD 95 switch receptor and the engineered T-cell receptor in the T-cell of the present invention may e.g. allow for the efficient incorporation of CD4 cells into TCR-T-cell therapy, such that it becomes possible to harness their unique properties to augment the antitumor immune response.
  • CD4 cells possess the ability to regulate the function of other immune cells, such as CD8 cytotoxic T-cells, dendritic cells, macrophages and B cells, by providing vital signals through the secretion of cytokines and direct cell-cell interactions.
  • This known helper function may be crucial for enhancing the persistence and potency of TCR-T-cells within the tumour microenvironment.
  • the invention provides an isolated T-cell, the T-cell comprising the vector according to the present invention.
  • the invention provides an isolated T-cell, the T-cell being introduced with, such as transfected, transduced or transformed with the vector according to the present invention.
  • the invention provides an isolated T-cell, the T-cell being treated, such as transfected, transduced or transformed to express the chimeric CD 95 receptor as herein described together with the engineered T-cell receptor.
  • the invention provides a kit comprising means to prepare the isolated and/or engineered T-cells according to the present invention.
  • the invention provides a pharmaceutical composition comprising the isolated T-cell according to the present invention.
  • the invention provides a method for preparing a T-cell for immunotherapy, comprising isolating T-cells from a human subject, introducing the vector, as herein provided into the T-cell, and expanding the T-cells in which the vector has been introduced.
  • the invention provides a pharmaceutical composition comprising T-cells expressing the chimeric CD 95 receptor as herein described and expressing an engineered T-cell receptor.
  • the invention provides a method for treating a patient having a disease, comprising administering to the patient the pharmaceutical composition according to the present invention.
  • the invention provides a method for treating a patient having a disease, comprising introducing in vivo the vector as herein provided into a T-cell of the patient.
  • the invention provides a method for increasing cytotoxicity of a T-cell in adoptive cell therapy, comprising - introducing a vector into the T- cell, wherein the vector comprises a nucleic acid encoding for a chimeric CD 95-receptor as herein described, and further encoding an engineered T-cell receptor.
  • the invention provides a chimeric CD 95 receptor; comprising a polypeptide, wherein said polypeptide comprises at least one CD 95 (- derived) polypeptide region having at least 60% sequence identity with a polypeptide domain, a polypeptide region or a polypeptide motif of a human CD 95 receptor as set forth in SEQ ID No.
  • said human CD 95 polypeptide region comprises a CD 95 extracellular ligand binding domain; further wherein said polypeptide comprises at least one non-CD 95 (-derived) co-stimulatory cytoplasmic polypeptide domain, region or motif, wherein said at least one cytoplasmic polypeptide domain or cytoplasmic polypeptide motif is a cytoplasmic polypeptide domain or cytoplasmic polypeptide motif selected from a group consisting of CD40L, CD2, TLR2, TLR4, and IL6R subunit beta.
  • the invention provides a chimeric CD 95 receptor; comprising a polypeptide, wherein said polypeptide comprises at least one CD 95 (- derived) polypeptide region comprising a CD 95 extracellular ligand binding domain; further wherein said polypeptide comprises at least one non-CD 95 (-derived) costimulatory cytoplasmic polypeptide domain, region or motif, wherein said at least one cytoplasmic polypeptide domain or cytoplasmic polypeptide motif is a cytoplasmic polypeptide domain or cytoplasmic polypeptide motif selected from a group consisting of CD40L, CD2, TLR2, TLR4, and IL6R subunit beta.
  • the chimeric CD 95 receptors are also able to turn negative signals e.g. present in a tumor microenvironment into positive signals for T-cell activation.
  • the chimeric CD 95 receptors as herein provided by linking the specific co-stimulatory cytoplasmic polypeptide domain/region/motif of CD40L, CD2, TLR2, TLR4, or IL6R subunit beta to at least one CD 95-derived polypeptide region that is still capable to bind to its natural ligand, provides the T-cell with resistance to the immunosuppressive tumor microenvironment, prevents TCR-T exhaustion and depletion through apoptosis, and stimulates TCR-T proliferation and functional activity.
  • this invention therefore provides T-cells and vectors comprising the chimeric CD 95 receptors according to the thirteenth aspect, and it is herewith contemplated that the chimeric CD 95 receptors according to the thirteenth aspect may be used in the compositions, kits and methods of the present invention.
  • T-cells comprising both an engineered T-cell receptor and a chimeric CD 95 receptor comprising a fusion of the specific co-stimulatory cytoplasmic domain of the specific non-CD95 (-derived) polypeptides as herein described, to the human CD 95 receptor polypeptide region comprising a functional CD 95 extracellular ligand binding domain, thereby constituting a switch receptor which is capable of turning negative signals (with respect to e.g. the T-cell’s activation status and/or cytotoxic capacity) into positive signals.
  • a switch receptor which is capable of turning negative signals (with respect to e.g. the T-cell’s activation status and/or cytotoxic capacity) into positive signals.
  • Fig. 1 shows a graphical representation of results from a flow cytometric analysis of T-cells transduced with chimeric CD 95 receptor polypeptides.
  • Fig. 2 shows a graphical representation of results from an in-vitro T-cell killing assay of T-cells according to the invention transduced with an engineered T-cell receptor and a chimeric CD 95 receptor polypeptide in HeLa cells.
  • Fig. 3 shows a graphical representation of results from an in-vitro T-cell killing assay of T-cells according to the invention transduced with an engineered T-cell receptor and chimeric CD 95 receptor polypeptides in NCIH 2030 cells.
  • Fig. 4 shows a graphical representation of results from an in-vitro T-cell killing assay of T-cells according to the invention transduced with an engineered T-cell receptor, a chimeric CD8 Co-receptor and a chimeric CD 95 receptor polypeptide in HeLa cells.
  • the invention is directed to an isolated T- cell, wherein the T-cell expresses a chimeric CD 95 receptor comprising a polypeptide, wherein said polypeptide comprises at least one CD 95 (-derived) polypeptide region having at least 60% sequence identity with a polypeptide domain, a polypeptide region or a polypeptide motif of a wildtype human CD 95 receptor (e.g. SEQ ID No.
  • said CD 95 (-derived) polypeptide region comprises a CD 95 extracellular ligand binding domain; further wherein said polypeptide comprises at least one non-CD 95 (-derived) costimulatory cytoplasmic polypeptide domain, region or motif of a tumor necrosis factor receptor superfamily protein comprising CD40, CD40L, CD27, HVEM, GITR, CD30, 0X40, and/or LTBR, an immunoglobulin superfamily (IgSF) protein, a Toll-like-receptor, and/or an I L6-receptor family protein; wherein the T-cell further expresses an engineered T-cell receptor.
  • a tumor necrosis factor receptor superfamily protein comprising CD40, CD40L, CD27, HVEM, GITR, CD30, 0X40, and/or LTBR, an immunoglobulin superfamily (IgSF) protein, a Toll-like-receptor, and/or an I L6-receptor family protein
  • the T-cell may express a chimeric CD 95 receptor comprising a polypeptide, wherein said polypeptide comprises at least one CD 95 (-derived) polypeptide region having one, two, or three cysteine-rich domains (CRDs) of a human CD 95 receptor, said one, two, or three CRDs selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, wherein said human CD 95 polypeptide region comprises a CD 95 extracellular ligand binding domain; further wherein said polypeptide comprises at least one non-CD 95 (-derived) co-stimulatory cytoplasmic polypeptide domain, region or motif of a tumor necrosis factor receptor superfamily protein comprising CD40, CD40L, CD27, HVEM, GITR, CD30, 0X40, and/or LTBR, an immunoglobulin superfamily (IgSF) protein, a Toll-like-receptor, and/or an IL6-receptor family
  • a particular example for a CRD to be included in the chimeric CD 95 receptor may be the CRD as set forth in SEQ ID NO: 3.
  • the expression of human wildtype CD 95 receptor relates to a protein having an amino acid sequence according to UniProtKB database entry No. P25445 ⁇ TNR6_HUMAN, as set forth e.g. in SEQ ID No. 1.
  • the chimeric CD 95 receptor comprising both a functional extracellular CD 95 receptor ligand binding domain and at least one non-CD 95-derived co-stimulatory cytoplasmic polypeptide domain, region or motif of a tumor necrosis factor receptor superfamily protein comprising CD40, CD40L, CD27, HVEM, GITR, CD30, 0X40, and/or LTBR, an immunoglobulin superfamily (IgSF) protein, a Toll-like-receptor, and/or an IL6-receptor family protein, when co-expressed in T-cells together with an engineered T-cell receptor, is able to turn negative signals (e.g.
  • IgSF immunoglobulin superfamily
  • cytoplasmic “death domain” of wildtype CD 95 amino acids 230-314 of SEQ ID No. 1
  • FADD Fas-Associated Death Domain-Containing Protein
  • a tumor necrosis factor receptor superfamily protein comprising CD40, CD40L, CD27, HVEM, GITR, CD30, 0X40, and/or LTBR
  • IgSF immunoglobulin superfamily
  • Toll-like-receptor a Toll-like-receptor
  • the T-cells as herein provided thus comprise chimeric CD 95 receptors that may act as a molecular switch, redirecting the signaling pathways triggered by FAS engagement with FASL. Instead of inducing apoptosis and T cell death, the fusion of the CD 95 receptor ligand binding domain to a co-stimulatory domain alters the intracellular signaling events, promoting T cell activation, persistence and enhanced anti-tumor responses.
  • a T-cell as herein provided comprising an engineered chimeric CD 95 receptor together with an engineered T-cell receptor into T cell therapy, the expression of FASL by solid tumors is rendered ineffective in hindering T cell function. This innovative approach empowers the T cells as herein provided to resist the immune evasion mechanisms deployed by solid tumors, enabling them to better recognize and eliminate tumor cells.
  • the extracellular ligand binding domain of the chimeric CD 95 receptor of the T-cell as herein provided may be functional in binding FAS- ligand (CD95L) or any other protein/polypeptide having the ability of binding to the wildtype CD 95 receptor ligand binding domain. Only for example, e.g. scFv and Fab have been described to have the capacity of binding to the ligand binding domain of wildtype CD 95 receptor.
  • the at least one CD 95 (-derived) polypeptide region has at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 97% sequence identity with the functional polypeptide domain or a functional polypeptide motif of a wildtype human CD 95 receptor (e.g. Seq ID No. 1).
  • the at least one CD 95 (-derived) polypeptide region may have one or more conservative amino acid substitutions relative to the amino acid sequence of the wildtype CD 95 receptor.
  • the at least one CD 95 (-derived) polypeptide region may have at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%, or at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%, or at least 80%, or at least 81 %, or at least 82%, or at least 83%, or at least 84%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91 %, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% sequence identity with the functional polypeptide domain or a functional polypeptide motif of a wildtype human CD 95 receptor (e.g. Seq ID No. 1).
  • a wildtype human CD 95 receptor e.g. Seq ID No
  • the human CD 95 polypeptide region comprising a CD 95 extracellular ligand binding domain may have generally a sufficient portion of the human wildtype CD 95 extracellular ligand binding domain to be functional in binding FASL.
  • said at least one CD 95-derived polypeptide region having at least 60% sequence identity with CD 95-derived FASL binding domain of a human wildtype CD 95 receptor may comprise the complete or a considerable part of the human wildtype CD 95 FASL binding domain and/or all amino acids at respective amino acid positions of the wildtype CD 95 receptor that are necessary and sufficient for FASL binding to the CD 95 receptor.
  • domain region As used herein are understood to relate to e.g. a region of the chimeric CD 95 receptor polypeptide which is necessary and/or sufficient for a biological function of the chimeric receptor, or to a region of the chimeric CD 95 receptor which is defined e.g. by a localization with respect to a cell, or to a structurally defined unit of the chimeric CD 95 receptor polypeptide.
  • cytoplasmic polypeptide domain and “cytoplasmic polypeptide motif” as used herein may be understood as relating to a region of the chimeric CD 95 receptor which is defined by its localization in the cytoplasm of a cell, and which is necessary and/or sufficient for a biological function of the chimeric receptor.
  • the chimeric CD 95 receptor polypeptide may be a single-chain polypeptide.
  • the CD 95 (-derived) polypeptide region may further comprise at least one, or at least two, or at least three CD 95 (-derived) cysteine- rich domains (CRDs).
  • the at least one CD 95 (-derived) CRD may comprise CRD 1 , CRD 2 and/or CRD 3 of the wildtype CD 95 receptor.
  • CRD 1 of the CD 95 wildtype receptor as referred to herein may relate to a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 2.
  • CRD 2 of the CD 95 wildtype receptor as referred to herein may relate to a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 3.
  • CRD 3 of the CD 95 wildtype receptor as referred to herein may relate to a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 4.
  • the CD 95 (- derived) polypeptide region may comprise CRD 1 , CRD 2 and CRD 3 of the wildtype CD 95 receptor.
  • CRD 1 , 2 and 3 polypeptide regions as included in the chimeric CD 95 receptor of the T-cell as herein provided may have one or more conservative amino acid substitutions relative to the CRD1 , 2, and 3 polypeptide regions of the wildtype CD 95 receptor.
  • all amino acid substitutions that maintain the functional activity of the wildtype CRD domains are envisaged. For example, Gary C.
  • the CD 95 polypeptide region may comprise CRD 2 of the CD 95 wildtype receptor as referred to herein may relate to a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 3 (optionally having one or more conservative amino acid substitutions relative to the CRD 2 polypeptide regions of the wildtype CD 95 receptor).
  • the at least one CD 95 (-derived) polypeptide region further comprises an extracellular N-terminal pre ligand assembly domain (PLAD) region.
  • the N-Terminal PLAD region of the CD 95 wildtype receptor as referred to herein may relate to a polypeptide comprising amino acid sequence 17-82 of UniProtKB database entry No. P25445 ⁇ TNR6_HUMAN, as set forth e.g. in SEQ ID No. 1.
  • the N- terminal PLAD region as referred to herein may relate to a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 5.
  • the PLAD region as included in the chimeric CD 95 receptor of the T-cell as herein provided may have one or more conservative amino acid substitutions relative to the PLAD region of the wildtype CD 95 receptor.
  • all amino acid substitutions that maintain the functional activity of the wildtype PLAD region are envisaged.
  • the at least one CD 95-derived polypeptide region may further comprise a CD95 wildtype homotypic interaction domain.
  • CD 95 homotypic interaction domain as referred to herein may relate to a polypeptide comprising amino acid sequence 59 - 82 of UniProtKB database entry No. P25445 ⁇ TNR6_HUMAN, as set forth e.g. in SEQ ID No. 1.
  • the homotypic interaction domain region as referred to herein may relate to a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 6.
  • the homotypic interaction domain as included in the chimeric CD 95 receptor of the T-cell as herein provided may have one or more conservative amino acid substitutions relative to the homotypic interaction domain of the wildtype CD 95 receptor.
  • all amino acid substitutions that maintain the functional activity of the wildtype homotypic interaction domain are envisaged.
  • the at least one CD 95 (-derived) polypeptide region may comprise a CD-95-derived transmembrane region.
  • the transmembrane domain of the CD 95 wildtype receptor as referred to herein may relate to a polypeptide comprising amino acid sequence 174-190 of UniProtKB database entry No. P25445 ⁇ TNR6_HUMAN, as set forth e.g. in SEQ ID No. 1.
  • the transmembrane domain of wildtype CD 95 as referred to herein may relate to a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 7.
  • the transmembrane domain as included in the chimeric CD 95 receptor of the T-cell as herein provided may have one or more conservative amino acid substitutions relative to the transmembrane domain of the wildtype CD 95 receptor.
  • all amino acid substitutions that maintain the functional activity of the wildtype transmembrane domain are envisaged.
  • the chimeric CD 95 receptor polypeptide of the T-cell as herein provided may comprise, in addition to comprising the CD 95 (-derived) ligand binding domain, and in addition to comprising the costimulatory domain of CD40, CD40L, CD27, HVEM, GITR, CD30, 0X40, and/or LTBR, an immunoglobulin superfamily (IgSF) protein, a Toll-like-receptor, and/or an IL6-receptor family protein, further domain regions /motif regions/ binding site regions from a wildtype human CD 95 receptor in every conceivable combination to establish a functional chimeric CD 95 receptor polypeptide.
  • IgSF immunoglobulin superfamily
  • “Functional” chimeric CD 95 receptor in this context relates to a chimeric CD 95 receptor that is capable of redirecting the signaling pathways triggered by FAS engagement with FASL such that - instead of inducing apoptosis and T-cell death - binding of FASL promotes T-cell activation, persistence and enhanced anti-tumor responses of the T-cell as herein provided.
  • an optional test for functionality of a chimeric CD 95 receptor may be an in-vitro T-cell killing assay as described e.g. by Kalbasi, A., Siurala, M., Su, L.L. et al. “Potentiating adoptive cell therapy using synthetic IL-9 receptors”.
  • the expression “every conceivable combination” of CD 95 receptor regions as described above is meant to exclude a combination with wildtype human CD 95 receptor domains/regions/motifs being inhibitory and/or promoting apoptosis and T-cell death.
  • the chimeric CD 95 receptor polypeptide of the T-cell as herein provided may lack the “death domain” of wildtype CD 95 (amino acids 230-314 of SEQ ID No. 1), or may merely comprise a altered “death domain” which no longer functions in promoting cell death and/or apoptosis of the T-cell, e.g. due to mutations which abolish any inhibitory and/or apoptosis and/or cell-death promoting functionality of the “death domain”.
  • the CD 95 (-derived) polypeptide region may comprise a complete wildtype CD 95 receptor extracellular domain.
  • the expression “wildtype CD 95 receptor extracellular domain” as referred to herein may relate to a polypeptide comprising amino acid sequence 26-173 of UniProtKB database entry No. P25445 ⁇ TNR6_HUMAN, as set forth e.g. in SEQ ID No. 1.
  • the wildtype CD 95 receptor extracellular domain as referred to herein may relate to a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 8.
  • the CD 95 receptor extracellular domain as included in the chimeric CD 95 receptor of the T-cell as herein provided may have one or more conservative amino acid substitutions relative to the extracellular domain of the wildtype CD 95 receptor.
  • all amino acid substitutions that maintain the functional activity of the wildtype CD 95 extracellular domain are envisaged.
  • the CD 95-derived polypeptide region may comprise a complete wildtype CD 95 receptor extracellular domain, and an entire CD 95- derived transmembrane domain.
  • the transmembrane domain of the chimeric CD 95 receptor of the T-cell as herein provided may be derived from other proteins which comprise a transmembrane domain.
  • the transmembrane domain may be derived from a co-stimulatory molecule.
  • any transmembrane domain which is functional and allows surface detectable expression of the chimeric CD 95 receptor is herewith envisaged.
  • the chimeric CD 95 receptor of the T-cell as herein provided may further comprise at least one linker region.
  • This may be e.g. a polypeptide linker region.
  • Such linker(s) may be included e.g. between functional domains/regions/motifs of the chimeric CD 95 receptor. It may be a linker region naturally occurring e.g. in wildtype CD 95 receptor, or e.g. in co-stimulatory proteins, e.g. in costimulatory proteins from which the costimulatory domain of the receptor is derived.
  • polypeptide linker regions may be included between the transmembrane domain and the ligand binding domain, and/or between the transmembrane domain and a CRD domain of the chimeric CD 95 receptor, and/or between individual CRDs (in embodiments comprising more than one CRD), and/or between the transmembrane domain and the intracellular co-stimulatory domain, and/or between individual co-stimulatory domains (in embodiments comprising more than one co-stimulatory domains).
  • Such linker region may comprise 1-100 amino acids, or e.g. 1-80 amino acids, or e.g. 1-50 amino acids, or e.g. 5-100 amino acids.
  • each (polypeptide) linker known in the art is herewith envisaged as being potentially included in the chimeric CD 95 switch receptor of the present invention.
  • the chimeric CD 95 receptor polypeptide of the T-cell as herein provided may comprise at least one cytoplasmic polypeptide domain or cytoplasmic polypeptide motif of CD40, CD40L, CD27, HVEM, GITR, CD30, 0X40, and/or LTBR, an immunoglobulin superfamily (IgSF) protein, a Toll-like-receptor, and/or an IL6-receptor family protein.
  • IgSF immunoglobulin superfamily
  • cytoplasmic co-stimulatory domains of family members of immunoglobulin superfamily (IgSF) protein, a Toll-like-receptor, and/or an IL6-receptor family protein or alternatively any one of the TNF-family members CD40, CD40L, CD27, HVEM, GITR, CD30, 0X40, and/or LTBR may be fused to the at least one CD 95-derived polypeptide region comprising a functional CD 95 receptor extracellular ligand binding domain in order to generate a functional chimeric CD 95 switch receptor capable of redirecting the signaling pathways triggered by FAS engagement with FASL such that - instead of inducing apoptosis and T-cell death - binding of FASL promotes T-cell activation, persistence and enhanced anti-tumor responses of the T-cell as herein provided, when the T-cell at the same time comprises/expresses an engineered T-cell receptor.
  • IgSF immunoglobulin superfamily
  • T-cell co-stimulatory domain or motif may relate to a protein portion which is necessary and/or sufficient to preserve the ability to propagate a co-stimulatory signal in a co-stimulatory molecule/protein as herein described.
  • Hong Ye et al., 1999 which is incorporated herein by reference, discloses - by way of example - TRAF-2 binding sites of diverse TNF-family members that may serve as T-cell co-stimulatory domain or motif in the sense of the present application.
  • the skilled person is further aware of numerous further “T-cell co-stimulatory domain or motif” that have been described in literature.
  • an amino acid sequence which is necessary and/or sufficient to preserve the ability to propagate a co- stimulatory signal in a co-stimulatory molecule/protein in the sense of the present invention may therefore e.g. comprise or consist of amino acids 170-177 of SEQ ID No. 28 as herein disclosed.
  • the at least one cytoplasmic polypeptide domain or cytoplasmic polypeptide motif selected from the group consisting of CD40, CD40L, CD27, ICOS, HVEM, GITR, CD30, CD2, 0X40, LTBR, CD28, TLR2, TLR4, and IL6R subunit beta may have an amino acid sequence having at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%, or at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%, or at least 80%, or at least 81 %, or at least 82%, or at least 83%, or at least 84%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91 %, or at least 92%, or at least 93%, or at least 94%, or at least 95%,
  • the chimeric CD 95 receptor of the T-cell as herein provided may comprise at least one cytoplasmic polypeptide domain, region or motif of CD28.
  • a cytoplasmic polypeptide region of CD28 may comprise the complete cytoplasmic domain of wildtype human CD28.
  • the cytoplasmic polypeptide region of CD28 included in the chimeric CD 95 receptor may comprise at least one functional, co-stimulatory motif/domain/region of the complete wildtype human CD28 cytoplasmic domain.
  • the expression “wildtype human CD28 cytoplasmic domain” as referred to herein may relate to a polypeptide comprising amino acid sequence 180-220 of UniProtKB database entry No.
  • the cytoplasmic polypeptide domain, region or motif of wildtype CD28 as included in the chimeric CD 95 receptor of the T-cell as herein provided may have one or more conservative amino acid substitutions relative to the amino acid sequence as set forth in SEQ ID No. 13.
  • all amino acid substitutions that maintain the functional activity of the cytoplasmic polypeptide domain, region or motif of wildtype CD28 are envisaged.
  • wildtype human 4-1 BB cytoplasmic domain may relate to a polypeptide comprising amino acid sequence 214-255 of UniProtKB database entry No. Q07011 ⁇ TNR9_HUMAN, as set forth e.g. in SEQ ID No. 14. It is herewith envisaged that the cytoplasmic polypeptide domain, region or motif of wildtype 4-1 BB as included in the chimeric CD 95 receptor of the T-cell as herein provided may have one or more conservative amino acid substitutions relative to the amino acid sequence as set forth in SEQ ID No. 14. In particular, all amino acid substitutions that maintain the functional activity of the cytoplasmic polypeptide domain, region or motif of wildtype 4-1 BB are envisaged.
  • the chimeric CD 95 receptor of the T-cell as herein provided may comprise at least one cytoplasmic polypeptide domain, region or motif of ICOS.
  • a cytoplasmic polypeptide region of ICOS may comprise the complete cytoplasmic domain of wildtype human ICOS.
  • the cytoplasmic polypeptide region of ICOS included in the chimeric CD 95 receptor may comprise at least one functional, co-stimulatory motif/domain/region of the complete wildtype human ICOS cytoplasmic domain.
  • the expression “wildtype human ICOS cytoplasmic domain” as referred to herein may relate to a polypeptide comprising amino acid sequence 162-199 of UniProtKB database entry No.
  • the polypeptide of the chimeric CD 95 receptor may have an amino acid sequence with at least 85% identity to the amino acids as set forth in SEQ ID NO: 17.
  • the chimeric CD 95 receptor of the T-cell as herein provided may comprise at least one cytoplasmic polypeptide domain, region or motif of HVEM.
  • a cytoplasmic polypeptide region of HVEM may comprise the complete cytoplasmic domain of wildtype human HVEM.
  • the cytoplasmic polypeptide region of HVEM included in the chimeric CD 95 receptor may comprise at least one functional, co-stimulatory motif/domain/region of the complete wildtype human HVEM cytoplasmic domain.
  • the expression “wildtype human HVEM cytoplasmic domain” as referred to herein may relate to a polypeptide comprising amino acid sequence 224-283 of UniProtKB database entry No.
  • the cytoplasmic polypeptide domain, region or motif of wildtype HVEM as included in the chimeric CD 95 receptor of the T-cell as herein provided may have one or more conservative amino acid substitutions relative to the amino acid sequence as set forth in SEQ ID No. 18.
  • all amino acid substitutions that maintain the functional activity of the cytoplasmic polypeptide domain, region or motif of wildtype HVEM are envisaged.
  • the polypeptide of the chimeric CD 95 receptor may have an amino acid sequence with at least 85% identity to the amino acids as set forth in SEQ ID NO: 19.
  • the chimeric CD 95 receptor of the T-cell as herein provided may comprise at least one cytoplasmic polypeptide domain, region or motif of 0X40.
  • a cytoplasmic polypeptide region of 0X40 may comprise the complete cytoplasmic domain of wildtype human 0X40.
  • the cytoplasmic polypeptide region of 0X40 included in the chimeric CD 95 receptor may comprise at least one functional, co-stimulatory motif/domain/region of the complete wildtype human 0X40 cytoplasmic domain.
  • wildtype human 0X40 cytoplasmic domain may relate to a polypeptide comprising amino acid sequence 236-277 of UniProtKB database entry No. P43489- TNR4_HUMAN, as set forth e.g. in SEQ ID No. 20. It is herewith envisaged that the cytoplasmic polypeptide domain, region or motif of wildtype 0X40 as included in the chimeric CD 95 receptor of the T-cell as herein provided may have one or more conservative amino acid substitutions relative to the amino acid sequence as set forth in SEQ ID No. 20. In particular, all amino acid substitutions that maintain the functional activity of the cytoplasmic polypeptide domain, region or motif of wildtype 0X40 are envisaged.
  • the polypeptide of the chimeric CD 95 receptor may have an amino acid sequence with at least 85% identity to the amino acids as set forth in SEQ ID NO: 21.
  • the chimeric CD 95 receptor of the T-cell as herein provided may comprise at least one cytoplasmic polypeptide domain, region or motif of CD27.
  • a cytoplasmic polypeptide region of CD27 may comprise the complete cytoplasmic domain of wildtype human CD27.
  • the cytoplasmic polypeptide region of CD27 included in the chimeric CD 95 receptor may comprise at least one functional, co-stimulatory motif/domain/region of the complete wildtype human CD27 cytoplasmic domain.
  • the expression “wildtype human CD27 cytoplasmic domain” as referred to herein may relate to a polypeptide comprising amino acid sequence 213-260 of UniProtKB database entry No.
  • the cytoplasmic polypeptide domain, region or motif of wildtype CD27 as included in the chimeric CD 95 receptor of the T-cell as herein provided may have one or more conservative amino acid substitutions relative to the amino acid sequence as set forth in SEQ ID No. 22.
  • all amino acid substitutions that maintain the functional activity of the cytoplasmic polypeptide domain, region or motif of wildtype CD27 are envisaged.
  • the polypeptide of the chimeric CD 95 receptor may have an amino acid sequence with at least 85% identity to the amino acids as set forth in SEQ ID NO: 23.
  • the chimeric CD 95 receptor of the T-cell as herein provided may comprise at least one cytoplasmic polypeptide domain, region or motif of CD40L.
  • a cytoplasmic polypeptide region of CD40L may comprise the complete cytoplasmic domain of wildtype human CD40L.
  • the cytoplasmic polypeptide region of CD40L included in the chimeric CD 95 receptor may comprise at least one functional, co-stimulatory motif/domain/region of the complete wildtype human CD 40L cytoplasmic domain.
  • wildtype human CD40L cytoplasmic domain may relate to a polypeptide comprising amino acid sequence 1-22 of UniProtKB database entry P29965- CD40L_HUMAN, as set forth e.g. in SEQ ID No. 24. It is herewith envisaged that the cytoplasmic polypeptide domain, region or motif of wildtype CD40L as included in the chimeric CD 95 receptor of the T-cell as herein provided may have one or more conservative amino acid substitutions relative to the amino acid sequence as set forth in SEQ ID No. 24. In particular, all amino acid substitutions that maintain the functional activity of the cytoplasmic polypeptide domain, region or motif of wildtype CD40L are envisaged.
  • the polypeptide of the chimeric CD 95 receptor may have an amino acid sequence with at least 85% identity to the amino acids as set forth in SEQ ID NO: 25.
  • the chimeric CD 95 receptor of the T-cell as herein provided may comprise at least one cytoplasmic polypeptide domain, region or motif of GITR.
  • a cytoplasmic polypeptide region of GITR may comprise the complete cytoplasmic domain of wildtype human GITR.
  • the cytoplasmic polypeptide region of GITR included in the chimeric CD 95 receptor may comprise at least one functional, co-stimulatory motif/domain/region of the complete wildtype human GITR cytoplasmic domain.
  • wildtype human GITR cytoplasmic domain as referred to herein may relate to a polypeptide comprising amino acid sequence 184-241 of UniProtKB database entry Q9Y5LI5 ⁇ TNR18_HUMAN, as set forth e.g. in SEQ ID No. 26.
  • the cytoplasmic polypeptide domain, region or motif of wildtype GITR as included in the chimeric CD 95 receptor of the T-cell as herein provided may have one or more conservative amino acid substitutions relative to the amino acid sequence as set forth in SEQ ID No. 26.
  • all amino acid substitutions that maintain the functional activity of the cytoplasmic polypeptide domain, region or motif of wildtype GITR are envisaged.
  • the polypeptide of the chimeric CD 95 receptor may have an amino acid sequence with at least 85% identity to the amino acids as set forth in SEQ ID NO: 27.
  • the chimeric CD 95 receptor of the T-cell as herein provided may comprise at least one cytoplasmic polypeptide domain, region or motif of CD30.
  • a cytoplasmic polypeptide region of CD30 may comprise the complete cytoplasmic domain of wildtype human CD30.
  • the cytoplasmic polypeptide region of CD30 included in the chimeric CD 95 receptor may comprise at least one functional, co-stimulatory motif/domain/region of the complete wildtype human CD30 cytoplasmic domain.
  • wildtype human CD30 cytoplasmic domain as referred to herein may relate to a polypeptide comprising amino acid sequence 407-595 of UniProtKB database entry P28908 ⁇ TNR8_HUMAN, as set forth e.g. in SEQ ID No. 28. It is herewith envisaged that the cytoplasmic polypeptide domain, region or motif of wildtype CD30 as included in the chimeric CD 95 receptor of the T-cell as herein provided may have one or more conservative amino acid substitutions relative to the amino acid sequence as set forth in SEQ ID No. 28. In particular, all amino acid substitutions that maintain the functional activity of the cytoplasmic polypeptide domain, region or motif of wildtype CD30 are envisaged.
  • the polypeptide of the chimeric CD 95 receptor may have an amino acid sequence with at least 85% identity to the amino acids as set forth in SEQ ID NO: 29.
  • the chimeric CD 95 receptor of the T-cell as herein provided may comprise at least one cytoplasmic polypeptide domain, region or motif of CD2.
  • a cytoplasmic polypeptide region of CD2 may comprise the complete cytoplasmic domain of wildtype human CD2.
  • the cytoplasmic polypeptide region of CD2 included in the chimeric CD 95 receptor may comprise at least one functional, co-stimulatory motif/domain/region of the complete wildtype human CD2 cytoplasmic domain.
  • wildtype human CD2 cytoplasmic domain as referred to herein may relate to a polypeptide comprising amino acid sequence 236-351 of UniProtKB database entry P06729 ⁇ CD2_HUMAN, as set forth e.g. in SEQ ID No. 30. It is herewith envisaged that the cytoplasmic polypeptide domain, region or motif of wildtype CD2 as included in the chimeric CD 95 receptor of the T-cell as herein provided may have one or more conservative amino acid substitutions relative to the amino acid sequence as set forth in SEQ ID No. 30. In particular, all amino acid substitutions that maintain the functional activity of the cytoplasmic polypeptide domain, region or motif of wildtype CD2 are envisaged.
  • the polypeptide of the chimeric CD 95 receptor may have an amino acid sequence with at least 85% identity to the amino acids as set forth in SEQ ID NO.: 31.
  • the chimeric CD 95 receptor of the T-cell as herein provided may comprise at least one cytoplasmic polypeptide domain, region or motif of LTBR.
  • a cytoplasmic polypeptide region of LTBR may comprise the complete cytoplasmic domain of wildtype human LTBR.
  • the cytoplasmic polypeptide region of LTBR included in the chimeric CD 95 receptor may comprise at least one functional, co-stimulatory motif/domain/region of the complete wildtype human LTBR cytoplasmic domain.
  • wildtype human LTBR cytoplasmic domain may relate to a polypeptide comprising amino acid sequence 249-435 of UniProtKB database entry P36941 ⁇ TNR3_HUMAN, as set forth e.g. in SEQ ID No. 32. It is herewith envisaged that the cytoplasmic polypeptide domain, region or motif of wildtype LTBR as included in the chimeric CD 95 receptor of the T-cell as herein provided may have one or more conservative amino acid substitutions relative to the amino acid sequence as set forth in SEQ ID No. 32. In particular, all amino acid substitutions that maintain the functional activity of the cytoplasmic polypeptide domain, region or motif of wildtype LTBR are envisaged.
  • the chimeric CD 95 receptor of the T-cell as herein provided may comprise at least one cytoplasmic polypeptide domain, region or motif of TLR2.
  • a cytoplasmic polypeptide region of TLR2 may comprise the complete cytoplasmic domain of wildtype human TLR2.
  • the cytoplasmic polypeptide region of TLR2 included in the chimeric CD 95 receptor may comprise at least one functional, co-stimulatory motif/domain/region of the complete wildtype human TLR2 cytoplasmic domain.
  • wildtype human TLR2 cytoplasmic domain may relate to a polypeptide comprising amino acid sequence 610-784 of UniProtKB database entry 060603 ⁇ TLR2_HUMAN, as set forth e.g. in SEQ ID No. 33. . It is herewith envisaged that the cytoplasmic polypeptide domain, region or motif of wildtype TLR2 as included in the chimeric CD 95 receptor of the T-cell as herein provided may have one or more conservative amino acid substitutions relative to the amino acid sequence as set forth in SEQ ID No. 33. In particular, all amino acid substitutions that maintain the functional activity of the cytoplasmic polypeptide domain, region or motif of wildtype TLR2 are envisaged.
  • the chimeric CD 95 receptor of the T-cell as herein provided may comprise at least one cytoplasmic polypeptide domain, region or motif of TLR4.
  • a cytoplasmic polypeptide region of TLR4 may comprise the complete cytoplasmic domain of wildtype human TLR4.
  • the cytoplasmic polypeptide region of TLR4 included in the chimeric CD 95 receptor may comprise at least one functional, co-stimulatory motif/domain/region of the complete wildtype human TLR4 cytoplasmic domain.
  • wildtype human TLR4 cytoplasmic domain may relate to a polypeptide comprising amino acid sequence 653-839 of UniProtKB database entry 000206 ⁇ TLR4_HUMAN, as set forth e.g. in SEQ ID No. 34. It is herewith envisaged that the cytoplasmic polypeptide domain, region or motif of wildtype TLR4 as included in the chimeric CD 95 receptor of the T-cell as herein provided may have one or more conservative amino acid substitutions relative to the amino acid sequence as set forth in SEQ ID No. 34. In particular, all amino acid substitutions that maintain the functional activity of the cytoplasmic polypeptide domain, region or motif of wildtype TLR4 are envisaged.
  • the chimeric CD 95 receptor of the T-cell as herein provided may comprise at least one cytoplasmic polypeptide domain, region or motif of IL6R subunit beta.
  • a cytoplasmic polypeptide region of IL6R subunit beta may comprise the complete cytoplasmic domain of wildtype human IL6R subunit beta.
  • the cytoplasmic polypeptide region of IL6R subunit beta included in the chimeric CD 95 receptor may comprise at least one functional, costimulatory motif/domain/region of the complete wildtype human IL6R subunit beta cytoplasmic domain.
  • wildtype human IL6R subunit beta cytoplasmic domain may relate to a polypeptide comprising amino acid sequence 642-918 of UniProtKB database entry P40189 ⁇ IL6RB_HUMAN, as set forth e.g. in SEQ ID No. 35. It is herewith envisaged that the cytoplasmic polypeptide domain, region or motif of wildtype IL6R as included in the chimeric CD 95 receptor of the T-cell as herein provided may have one or more conservative amino acid substitutions relative to the amino acid sequence as set forth in SEQ ID No. 35. In particular, all amino acid substitutions that maintain the functional activity of the cytoplasmic polypeptide domain, region or motif of wildtype IL6R are envisaged.
  • CD 95 -derived polypeptide region may be used herein interchangeably with the expression “CD95 polypeptide region” to refer to a (functional) portion of a wildtype CD 95 protein (or variants thereof).
  • variants of wildtype CD 95 such a variant may have at least 60% sequence identity (e.g., at least 70%, 80%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or more) to the corresponding portion of the amino acid sequence of SEQ ID NO: 1.
  • variants of wildtype CD 95 as herein described may comprise an extracellular domain that preserves the ability to bind FASL. Suitable methods (such as e.g. surface plasmon resonance assay) for determining said functional ability are known to the skilled person.
  • a chimeric CD 95 receptor of the T-cell as herein provided may e.g. comprise a polypeptide having an amino acid sequence with at least 85% or at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91 %, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% identity to the amino acids as set forth in any one of the SEQ ID No’s selected from the group consisting of SEQ ID No. 12, 15, 17, 19, 21 , 23, 25, 27, 29, and 31.
  • a chimeric CD 95 receptor of the T-cell as herein provided may have one or more conservative amino acid substitutions relative to an amino acid sequence as set forth in any one of the SEQ ID No’s selected from the group consisting of SEQ ID No. 12, 15, 17, 19, 21 , 23, 25, 27, 29, and 31.
  • the invention provides a vector comprising a nucleic acid comprising a nuclear acid sequence encoding for a chimeric CD 95 receptor comprising a polypeptide, wherein said polypeptide comprises at least one CD 95 (-derived) polypeptide region having at least 60% sequence identity with a polypeptide domain, a polypeptide region or a polypeptide motif of a human CD 95 receptor as set forth in SEQ ID No.
  • said human CD 95 polypeptide region comprises a CD 95 extracellular ligand binding domain; further wherein said polypeptide comprises at least one non-CD 95 (- derived) co-stimulatory cytoplasmic polypeptide domain, region or motif of a tumor necrosis factor receptor superfamily protein comprising CD40, CD40L, CD27, HVEM, GITR, CD30, 0X40, and/or LTBR, an immunoglobulin superfamily (IgSF) protein, a Toll- like-receptor, and/or an IL6-receptor family protein; and further comprising a nucleic acid comprising a nuclear acid sequence encoding for an engineered T-cell receptor.
  • a tumor necrosis factor receptor superfamily protein comprising CD40, CD40L, CD27, HVEM, GITR, CD30, 0X40, and/or LTBR, an immunoglobulin superfamily (IgSF) protein, a Toll- like-receptor, and/or an IL6-
  • polynucleotide or “nucleic acid” as used herein comprises a sequence of polyribonucleotides and polydeoxribonucleotides, e.g. modified or unmodified RNA or DNA, each in single-stranded and/or double-stranded form linear or circular, or mixtures thereof, including hybrid molecules.
  • the nucleic acids according to this invention thus comprise DNA (such as dsDNA, ssDNA, cDNA), RNA (such as dsRNA, ssRNA, mRNA ivtRNA), combinations thereof or derivatives (such as RNA) thereof.
  • a polynucleotide may comprise a conventional phosphodiester bond or a non- conventional bond (e.g., an amide bond, such as found in peptide nucleic acids (RNA)).
  • the polynucleotides of the invention may also contain one or more modified bases, such as, for example, tritylated bases and unusual bases such as inosine. Other modifications, including chemical, enzymatic, or metabolic modifications, are also conceivable, as long as a binding molecule of the invention can be expressed from the polynucleotide.
  • the polynucleotide may be provided in isolated form as defined elsewhere herein.
  • a polynucleotide may include regulatory sequences such as transcription control elements (including promoters, enhancers, operators, repressors, and transcription termination signals), ribosome binding site, introns, or the like.
  • the present invention provides a polynucleotide comprising or consisting of a nucleic acid that is at least about 80 %, about 85 %, about 90 %, about 91 %, about 92 %, about 93 %, about 94 %, about 95 %, about 96 %, about 97 %, about 98 %, about 99 %, or 100 % identical to a reference polynucleotide sequence selected from the group consisting of sequences as depicted in SEQ ID NOs: 36-45.
  • the polynucleotides described above may or may not comprise additional or altered nucleotide sequences encoding e.g., altered amino acid residues.
  • the polynucleotides may further encode fusion polypeptides, fragments, variants and other derivatives of the chimeric CD 95 receptors described herein.
  • the nucleic acid sequences of the vectors of the present invention may be codon-optimized for optimal expression in the desired host T-cell, e.g. a human lymphocyte; or for expression in bacterial, yeast or insect T-cells that are particularly envisaged for the expression of a soluble TCR of the invention.
  • Codon-optimization refers to the exchange in a sequence of interest of codons that are generally rare in highly expressed genes of a given species by codons that are generally frequent in highly expressed genes of such species, such codons encoding the same amino acids as the codons that are being exchanged. Selection of optimum codons thus depends on codon usage of the host genome and the presence of several desirable and undesirable sequence motifs.
  • a “vector” as understood herein relates to a nucleic acid molecule used as a vehicle to transfer (foreign) genetic material into a host T-cell where it can for instance be replicated and/or expressed.
  • the vector may be a viral vector or a non-viral vector.
  • Viral vectors may be selected from adenoviruses, poxviruses, alphaviruses, arenaviruses, flaviruses, rhabdoviruses, retroviruses, lentiviruses, herpesviruses, paramyxoviruses, picornaviruses, and combinations thereof.
  • Viruses used for transfection of T-cells may include naturally occurring viruses as well as artificial viruses. Viruses may be either an enveloped or non-enveloped virus. Parvoviruses (such as AAVs) are examples of non-enveloped viruses.
  • the viruses may be enveloped viruses.
  • the viruses used for transfection of T-cells may be retroviruses and in particular lentiviruses.
  • Viral envelope proteins that can promote viral infection of eukaryotic cells may comprise HIV- 1 derived lentiviral vectors (LVs) pseudotyped with envelope glycoproteins (GPs) from the vesicular stomatitis virus (VSV-G), the modified feline endogenous retrovirus (RD114TR), and the modified gibbon ape leukemia virus (GALVTR).
  • LVs HIV- 1 derived lentiviral vectors
  • GPs envelope glycoproteins
  • VSV-G vesicular stomatitis virus
  • RD114TR modified feline endogenous retrovirus
  • GALVTR gibbon ape leukemia virus
  • viruses such as parvoviruses, including adeno- associated viruses (AAV), thereby demonstrating their broad efficiency.
  • viruses such as parvoviruses, including adeno- associated viruses (AAV), thereby demonstrating their broad efficiency.
  • other viral envelop proteins may be used including Moloney murine leukemia virus (MLV)
  • RD114 env chimeric envelope protein RD114pro or RDpro (which is an RD114-HIV chimera that was constructed by replacing the R peptide cleavage sequence of RD114 with the HIV-1 matrix/capsid (MA/CA) cleavage sequence, such as described in Bell et al. Experimental Biology and Medicine 2010; 235: 1269-1276; the content of which is incorporated herein by reference), baculovirus GP64 env (such as described in Wang et al. J. Virol.
  • vector encompasses, without limitation, plasmids, viral vectors (including retroviral vectors, lentiviral vectors, adenoviral vectors, vaccinia virus vectors, polyoma virus vectors, and adenovirus-associated vectors (AAV)), phages, phagemids, cosmids and artificial chromosomes (including BACs and YACs).
  • viral vectors including retroviral vectors, lentiviral vectors, adenoviral vectors, vaccinia virus vectors, polyoma virus vectors, and adenovirus-associated vectors (AAV)
  • phages phagemids
  • cosmids and artificial chromosomes including BACs and YACs.
  • the vector itself is generally a nucleotide sequence, commonly a DNA sequence that comprises an insert (transgene) and a larger sequence that serves as the “backbone” of the vector.
  • Engineered vectors typically comprise an origin for autonomous replication in the host-cells (if stable expression of the polynucleotide is desired), selection markers, and restriction enzyme cleavage sites (e.g. a multiple cloning site, MCS).
  • the vector may additionally comprise promoters, genetic markers, reporter genes, targeting sequences, other regulatory elements, and/or protein purification tags. As known to those skilled in the art, large numbers of suitable vectors are known to those of skill in the art and many are commercially available.
  • the vector may further comprise a nucleic acid encoding a T-cell receptor comprising a TCRa chain and a TCRp chain.
  • the engineered T-cell receptor may be a recombinant T-cell receptor.
  • the vector may further comprise a nucleic acid encoding for a CD8 Co-receptor.
  • the CD8 Co-receptor may be a wildtype CD8 Co-receptor. It is contemplated that the nucleic acid may encode e.g. a CD8a and a CD8p Co-receptor.
  • An advantage of incorporation of CD8 co-receptor into the vector is the resulting option of achieving a coordinated CD4+ and CD8+ TCR-T cell response in adoptive cell therapy which broadens and deepens clinical responses.
  • the CD8 Co-receptor may be a chimeric CD8 Co-receptor.
  • the chimeric CD8 Co- receptor may comprise a polypeptide, wherein said polypeptide comprises at least one CD8a-derived polypeptide region having at least 60% sequence identity with a functional polypeptide domain or a functional polypeptide motif of a human wildtype CD8a Co- receptor (e.g. Seq ID No. 46), wherein said least one CD8a-derived polypeptide region comprises an CD8a-derived IG-like domain region; further wherein said polypeptide comprises at least one CD8p-derived polypeptide region having at least 60% sequence identity with a functional polypeptide domain or a functional polypeptide motif of a human wildtype CD8p Co-receptor (e.g. Seq ID No. 47), wherein said least one CD8p-derived polypeptide region comprises an CD8p-derived IG-like domain region.
  • said polypeptide comprises at least one CD8a-derived polypeptide region having at least 60% sequence identity with a functional polypeptide domain or a functional polypeptide motif of a human wildtype CD
  • the expression human wildtype CD8a Co-receptor relates to a protein having an amino acid sequence according to UniProtKB database entry No. P01732 ⁇ CD8A_HUMAN, as set forth e.g. in SEQ ID No. 46. It is further understood that the expression human wildtype CD8p Co-receptor relates to a protein having an amino acid sequence according to UniProtKB database entry No. P10966 ⁇ CD8B_HUMAN, as set forth e.g. in SEQ ID No. 47.
  • the chimeric human CD8 Co-receptor polypeptide comprising both a CD8a (-derived) IG-like domain region together with a CD8p (-derived) IG-like domain region is able to maintain the function of a CD8a (-derived) IG-like domain region and a CD8p (-derived) IG-like domain region being present on individual, separate polypeptides in a wildtype CD8 ⁇ co-receptor.
  • the expression “Ig-like domain” as used herein may - in principle - refer to a polypeptide region that is homologous to the V and/or C domains in immunoglobulin proteins.
  • the at least one CD8a (-derived) polypeptide region has at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 97% sequence identity with the functional polypeptide domain or a functional polypeptide motif of a wildtype human CD8a Co-receptor (e.g. Seq ID No. 46).
  • a wildtype human CD8a Co-receptor e.g. Seq ID No. 46.
  • the at least one CD8a (-derived) polypeptide region may have at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%, or at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%, or at least 80%, or at least 81 %, or at least 82%, or at least 83%, or at least 84%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91 %, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% sequence identity with the functional polypeptide domain or a functional polypeptide motif of a wildtype human CD8a Co- receptor (e.g. Seq ID No. 46).
  • a wildtype human CD8a Co- receptor e
  • the at least one CD8p (-derived) polypeptide region has at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 97% sequence identity with the functional polypeptide domain or a functional polypeptide motif of a wildtype human CD8p Co-receptor (Seq ID No. 47).
  • the at least one CD8p (-derived) polypeptide region may have at least 70%, or at least 71%, or at least 72%, or at least 73%, or at least 74%, or at least 75%, or at least 76%, or at least 77%, or at least 78%, or at least 79%, or at least 80%, or at least 81 %, or at least 82%, or at least 83%, or at least 84%, or at least 85%, or at least 86%, or at least 87%, or at least 88%, or at least 89% or at least 90%, or at least 91 %, or at least 92%, or at least 93%, or at least 94%, or at least 95%, or at least 96% or at least 97%, or at least 98%, or at least 99%, or 100% sequence identity with the functional polypeptide domain or a functional polypeptide motif of a wildtype human CD8p Coreceptor (e.g. Seq ID No. 47).
  • a wildtype human CD8p Coreceptor e
  • the chimeric human CD8 Co-receptor polypeptide is a single-chain polypeptide.
  • the chimeric CD8 Co-receptor comprises the CD8a (derived) IG-like domain region, the CD8p derived IG-like domain region, a stalk region (typically between the transmembrane region and the IG-like domain region of CD8 receptors), a transmembrane domain region; and an intracellular/cytoplasmic domain region, wherein the intracellular domain region comprises a palmitoylation motif region and a LCK binding site region.
  • the stalk region, the transmembrane region, and the intracellular domain of the chimeric CD 8 Co-receptor may be derived from other proteins or from CD8a or CD8p.
  • the chimeric CD8 Co- receptor polypeptide may comprise, in addition to comprising the CD8a (-derived) IG-like domain region and the CD8p (-derived) IG-like domain region, further domain regions /motif regions/ binding site regions from one or both of a wildtype human CD8a Co- receptor and/or a wildtype human CD8p Co-receptor, and/or from other proteins in every conceivable combination to establish a functional chimeric CD8 Co-receptor polypeptide.
  • the chimeric CD8 Co-receptor may comprise a CD8a-derived transmembrane region.
  • the chimeric CD8 receptor may comprise a CD4 Co-receptor (derived) cytoplasmic region.
  • the chimeric CD8 co-receptor may comprise the entire cytoplasmic region of a wildtype CD4 Co-receptor.
  • the expression “wildtype human CD4 Co-receptor cytoplasmic region” as referred to herein may relate to a polypeptide comprising amino acid sequence 419 - 458 of UniProtKB database entry No. P01730 ⁇ CD4_HUMAN, as set forth e.g. in SEQ ID No. 48.
  • the chimeric CD8 Co-receptor may further comprise at least one cytoplasmic polypeptide domain or cytoplasmic polypeptide motif of a tumor necrosis factor receptor superfamily protein, of an immunoglobulin superfamily (IgSF) protein, and/or of and/or of an ITAM-associated receptor.
  • IgSF immunoglobulin superfamily
  • the enhanced chimeric CD8 Co-receptor which - in some embodiments - is encoded by the vector of the present invention links an extra co-stimulatory domain to the human CD8 Receptor.
  • the co-stimulation associated with such co-stimulatory domain provided by the fused cytoplasmic polypeptide domain or cytoplasmic polypeptide motif of a tumor necrosis factor receptor superfamily protein and/or of an immunoglobulin superfamily (IgSF) protein, and/or of an ITAM-associated receptor complements TCR signaling, leading to a more potent TCR-T-cell product.
  • IgSF immunoglobulin superfamily
  • T-cells as herein provided comprising the chimeric CD 95 receptor, the engineered T-cell receptor and, in addition, a chimeric CD8 Co-receptor therefore exhibit enhanced T-cell activation, proliferation, cytokine production, and cytotoxicity, ultimately improving the therapeutic efficacy of TCR-T-cell therapy.
  • the chimeric CD8 Co-receptor comprises a CD4 (-derived) cytoplasmic domain.
  • the at least one CD8a (-derived) polypeptide region may also further comprise a CD8a (-derived) Transmembrane domain region and the at least one CD8p (-derived) polypeptide region may comprise a CD8p (-derived) stalk domain region.
  • the CD8a (-derived) IG-like domain region may be located closer to the N-terminal end of the enhanced chimeric CD8 Co-receptor polypeptide than the CD8p (-derived) IG-like domain region.
  • the chimeric CD8 Co-receptor may further comprise a costimulatory CD30 motif, as set forth e.g. in SEQ ID No. 49 as herewith presented.
  • the chimeric CD8 Co-receptor according to this embodiment may comprise the cytoplasmic domain of CD40.
  • the polypeptide linker sequence GGGS is inserted between the CD30 costimulatory motif and the CD40 cytoplasmic domain.
  • the CD30 motif may be included at the C-terminal end of the chimeric CD8 Co-receptor.
  • An enhanced chimeric CD8 Co-receptor in accordance with this embodiment may e.g.
  • the transgene may further include one or more multicistronic element(s) and the multicistronic element(s) may be positioned, for example, between any two nucleic acid sequences encoding for the chimeric CD 95 receptor, TCRa, TCRp, and the optional CD8 Coreceptor.
  • the multicistronic element(s) may include a sequence encoding a ribosome skip element selected from among a T2A, a P2A, a E2A or a F2A or an internal ribosome entry site (IRES).
  • the term “self-cleaving 2A peptide” refers to relatively short peptides (of the order of 20 amino acids long, depending on the virus of origin) acting co- translationally, by preventing the formation of a normal peptide bond between the glycine and last proline, resulting in the ribosome skipping to the next codon, and the nascent peptide cleaving between the Gly and Pro. After cleavage, the short 2A peptide remains fused to the C-terminus of the 'upstream’ protein, while the proline is added to the N- terminus of the 'downstream’ protein.
  • Self-cleaving 2A peptide may be selected from porcine teschovirus-1 (P2A), equine rhinitis A virus (E2A), Thosea asigna virus (T2A), foot- and-mouth disease virus (F2A), or any combination thereof.
  • P2A porcine teschovirus-1
  • E2A equine rhinitis A virus
  • T2A Thosea asigna virus
  • F2A foot- and-mouth disease virus
  • an isolated T-cell comprising a nucleic acid encoding for the chimeric human CD 95 receptor of the present invention, wherein the nucleic acid further encodes for an engineered T-cell receptor.
  • engineered T-cell receptor is to be distinguished from a “CAR” T-cell receptor.
  • CAR chimeric antigen receptors
  • engineered TCRs recognize HLA- presented peptides derived from proteins of all cellular compartments.
  • the expression “engineered T-cell receptor” is understood to embrace TCRs that are not naturally expressed by the recited T cell (e.g., TCRs that are exogenous to the T cell and that are introduced into the T cell genome by way of a genetic engineering technique described herein).
  • a T-cell may express the chimeric CD 95 receptor as herein described and the engineered T-cell receptor.
  • the T-cell may, in some embodiments, further express a CD8 co-receptor such as a wildtype CD8 co-receptor or a chimeric CD8 co-receptor.
  • a CD8 co-receptor such as a wildtype CD8 co-receptor or a chimeric CD8 co-receptor.
  • the chimeric CD8 coreceptor may be a chimeric receptor having functionality of a wildtype CD8 Co-receptor.
  • the chimeric CD8 co-receptor may have the same MHC-complex binding functionality as a wildtype CD8 Co-receptor.
  • the T-cell may be a CD4 T-cell, and further the CD4 T-cell may additionally expresses a recombinant human CD8 co-receptor, such as e.g. a CD8a and CD8p receptor, or a chimeric CD8 co-receptor.
  • a recombinant human CD8 co-receptor such as e.g. a CD8a and CD8p receptor, or a chimeric CD8 co-receptor.
  • the vector and as herein described may have been introduced into the T-cell.
  • the (isolated) T-cells may be generated using various methods, including those recognized in the literature.
  • a polynucleotide encoding an expression cassette that comprises a tumor recognition, or another type of recognition moiety, and that also encodes for the chimeric CD 95 receptors as herein described and the engineered T-cell receptor and, optionally a CD8 Co-receptor may be stably introduced into the T-cell by a transposon/transposase system or a viral-based gene transfer system, such as a lentiviral or a retroviral system, or another suitable method, such as transfection, electroporation, transduction, lipofection, calcium phosphate (CaPCll), nanoengineered substances, such as Ormosil, mRNA-based therapy, viral delivery methods, including adenoviruses, retroviruses, lentiviruses, adeno-associated viruses, or another suitable method. It is envisaged that T-cells may be generated by in vivo
  • the T-cells may be transfected by means known in the art including lipofection (liposome-based transfection), electroporation, calcium phosphate transfection, biolistic particle delivery (e.g., gene guns), microinjection, or combinations thereof.
  • lipofection liposome-based transfection
  • electroporation calcium phosphate transfection
  • biolistic particle delivery e.g., gene guns
  • microinjection or combinations thereof.
  • Various methods of transfecting cells are known in the art. See, e.g., Sambrook & Russell (Eds.) Molecular Cloning: A Laboratory Manual (3rd Ed.) Volumes 1-3 (2001) Cold Spring Harbor Laboratory Press; Ramamoorth & Narvekar “Non Viral Vectors in Gene Therapy- An Overview.” JCIinDiagn Res. (2015) 9(1): GE01-GE06.
  • the cell may be a ⁇ T-cell, y ⁇ T-cell, and/or a natural killer T-cell.
  • the ⁇ T-cell may be a CD4 T-cell, or the ⁇ T-cell may be a CD8 T-cell, or the y ⁇ T-cell may comprise e.g. a Vy1 chain or a Vy2 chain, or may be e.g. a Vy9V82+ T-cell.
  • the T-cell may express a chimeric CD 95 receptor as herein described, as well as an engineered T-cell receptor.
  • the T-cell may be a CD 4 T-cell that further expresses the CD 8 Co-receptor, e.g. both CD8a and CD8p Co-receptor, or any engineered protein exhibiting Co-receptor functionality.
  • the T-cells further express an engineered T-cell receptor.
  • Engineered T-cells of the present disclosure can be used to treat a subject in need of treatment for a condition, for example, a cancer described herein.
  • the T-cells may be ⁇ T-cells or y ⁇ T-cells that express the chimeric CD 95 receptor polypeptide as described herein, and furthermore an engineered TCR.
  • the T- cells may express a CD8 Co-receptor such as a wildtype or chimeric CD8 co-receptor.
  • T- cells described herein may be used to treat a cancer, including solid tumors and hematologic malignancies. For example, “hot” tumors or “cold” tumors may be treated by the T-cells herewith provided.
  • the engineered T-cell receptor as herein described may specifically bind a MAGE antigen family member, such as MAGE-A1 or Mage-A4, or wherein the engineered T-cell receptor may specifically bind an antigen selected from the group consisting of a PRAME antigen, a NY-ESO-1 antigen, a GP100 antigen, an AFP antigen, a Col6A3 antigen, an HPV-16 antigen, a WT1 antigen, an HA1 antigen, an HA2 antigen, a mutated KRAS antigen, a mutated NRAS antigen, a mutated HRAS antigen, a mutated TP53 antigen, and an EGFR antigen.
  • a PRAME antigen such as MAGE-A1 or Mage-A4
  • a GP100 antigen such as MAGE-A1 or Mage-A4
  • an antigen selected from the group consisting of a PRAME antigen, a NY-ESO-1 antigen,
  • the expression “mutated” with respect to specific tumor antigens as herein used relates to well-known mutations within the epitope region of the respective protein, polypeptide or peptide that has been correlated with expression in a human cancer.
  • the T-cells described herein may also be used to treat an infectious disease.
  • the T-cells described herein may be used to treat an infectious disease, an infectious disease may be caused a virus.
  • the T-cells described herein may be used to treat an immune disease, such as an autoimmune disease.
  • the T- cells may be ⁇ T-cells or y ⁇ T-cells that express a chimeric CD 95 receptor as described herein, and an engineered TCR, and optionally a CD8 Co-receptor such as a wildtype or chimeric CD8 co-receptor.
  • the T-cell may be derived from an induced pluripotent stem cell (iPSCs).
  • iPSCs induced pluripotent stem cell
  • kits comprising means to prepare the T-cells described above.
  • this invention relates to a pharmaceutical composition comprising the T-cell provided by the present invention.
  • the pharmaceutical composition may further comprise an adjuvant, excipient, buffer, diluent, carrier, stabilizer or combination thereof.
  • composition comprising T-cells which express the chimeric CD 95 receptor as herein described and an engineered T-cell receptor.
  • the pharmaceutical composition may further comprise CD4 T-cells expressing said chimeric CD 95 receptor, an engineered T-cell receptor and further expressing a recombinant CD8 Co-receptor, such as e.g. a CD8a receptor and a CD8p receptor, or a chimeric CD8 receptor.
  • the pharmaceutical composition may further comprise one or more pharmaceutically acceptable carriers. Any pharmaceutically acceptable carrier can be used, as long as the carrier does not impact the viability of the T-cells to be administered is suitable for the chosen route of administration of the pharmaceutical composition.
  • the pharmaceutical acceptable carrier may be a physiological saline solution, optionally with components such as human serum albumin that can improve the viability of the T-cells that express the chimeric CD 95 receptor. It is also possible that the chimeric CD 95 receptor expressing T-cells are stored, after their manufacture, in frozen form, for example at a temperature of between -20°C and -80 °C.
  • the pharmaceutical composition may contain cryo-protectants that have been added to protect the cells from being damaged by the freezing process. Examples of cryoprotectants that may be used here for the freezing of the pharmaceutical composition containing transduced T-cells include glycerol, DMSO.
  • cryoprotectants can be used together with crystalloid solutions such as commercially available HypoThermosol® or PlasmaLyte-A solution which are both approved for infusion and are available in pharmaceutical grade.
  • Other possible media that can be used as carrier in the pharmaceutical composition are media of the “CryoStor family”, commercially available animal protein-free defined cryopreservation media from Biolife Solutions such as CyroStor2 (CS2, an optimized freeze media pre-formulated with 2% DMSO), CyroStor5 (CS5, an optimized freeze media pre-formulated with 5% DMSO), or CyroStorlO (CS10, an optimized freeze media preformulated with 10% DMSO).
  • a method for preparing a T-cell for immunotherapy comprising isolating T-cells from a human subject, introducing the vector comprising a nucleic acid encoding for a chimeric CD 95 receptor comprising a polypeptide, wherein said polypeptide comprises at least one CD 95-derived polypeptide region having at least 60% sequence identity with a polypeptide domain, a polypeptide region or a polypeptide motif of a human CD 95 receptor as set forth in SEQ ID No.
  • said human CD 95 polypeptide region comprises a CD 95 extracellular ligand binding domain; further wherein said polypeptide comprises at least one non-CD 95-derived costimulatory cytoplasmic polypeptide domain, region or motif of a tumor necrosis factor receptor superfamily protein comprising CD40, CD40L, CD27, HVEM, GITR, CD30, 0X40, and/or LTBR, an immunoglobulin superfamily (IgSF) protein, a Toll-like- receptor, and/or an I L6-receptor family protein; and further comprising a nucleic acid encoding for an engineered T-cell receptor into the T-cell, and expanding the transduced T-cells.
  • a tumor necrosis factor receptor superfamily protein comprising CD40, CD40L, CD27, HVEM, GITR, CD30, 0X40, and/or LTBR, an immunoglobulin superfamily (IgSF) protein, a Toll-like- receptor, and/or an I L6
  • the method may comprise transforming, transfecting or transducing the isolated T-cells with the vector.
  • a method for treating a patient having a disease comprising introducing in vivo the vector as herein disclosed into a T-cell of the patient.
  • the nucleic acid may be a DNA or an mRNA.
  • the vector may be - for example - a nonreplicating viral vector.
  • the nucleic acid may be mRNA, and the mRNA may be in vivo introduced into the T-cell of the patient using nanoparticles, such as lipid nanoparticles.
  • the disease may be e.g. an autoimmune disease or a cancer.
  • a cancer treated by the method may be selected from the group consisting of non-small cell lung cancer, small cell lung cancer, pancreatic cancer, ovarian cancer, melanoma, breast cancer, liver cancer, kidney cancer, esophageal cancer, brain cancer, gastric cancer, Merkel cell carcinoma, leukemia, urinary bladder cancer, uterine cancer, colorectal cancer, gallbladder cancer, bile duct cancer, and prostate cancer.
  • the cancer treated may be a solid tumor.
  • the lung cancer may be, but is not limited to, non-small cell lung cancer (NSCLC), including squamous cell carcinoma of the lung, adenocarcinoma of the lung, large cell carcinoma of the lung and other histologic types of NSCLC) or small cell lung cancer, too ment.
  • the breast cancer may be, but is not limited to, ductal breast cancer, ductal-invasive breast cancer, invasive breast cancer, tubular breast cancer, medullary breast cancer or combinations thereof.
  • the gastric cancer may be gastric adenocarcinoma or squamous cell cancer.
  • the sarcoma cancer may be, but is not limited to, chondrosarcoma cancer, osteosarcoma cancer or combinations thereof.
  • the adenoma cancer may include, but is also not limited to, gastric adenocarcinoma, pancreatic adenocarcinoma or combinations thereof.
  • a method for increasing cytotoxicity of a T-cell in adoptive cell therapy comprising introducing a vector into a T-cell, wherein the vector comprises a nucleic acid encoding for an engineered T-cell receptor and further encoding for a chimeric CD 95 receptor comprising a polypeptide, wherein said polypeptide comprises at least one CD 95-derived polypeptide region having at least 60% sequence identity with a polypeptide domain, a polypeptide region or a polypeptide motif of a human CD 95 receptor as set forth in SEQ ID No.
  • said human CD 95 polypeptide region comprises a CD 95 extracellular ligand binding domain; further wherein said polypeptide comprises at least one non-CD 95-derived co-stimulatory cytoplasmic polypeptide domain, region or motif of a tumor necrosis factor receptor superfamily protein comprising CD40, CD40L, CD27, HVEM, GITR, CD30, 0X40, and/or LTBR, an immunoglobulin superfamily (IgSF) protein, a Toll-like-receptor, and/or an IL6-receptor family protein.
  • a tumor necrosis factor receptor superfamily protein comprising CD40, CD40L, CD27, HVEM, GITR, CD30, 0X40, and/or LTBR, an immunoglobulin superfamily (IgSF) protein, a Toll-like-receptor, and/or an IL6-receptor family protein.
  • IgSF immunoglobulin superfamily
  • the nucleic acid may further encode for a recombinant CD8 Coreceptor, such as a wildtype CD8 co-receptor or a chimeric CD 8 co-receptor.
  • a recombinant CD8 Coreceptor such as a wildtype CD8 co-receptor or a chimeric CD 8 co-receptor.
  • the T-cell receptor may be a recombinant T-cell receptor that specifically binds a tumor specific antigen.
  • this may be a MAGE antigen such as e.g. a Mage-A1 antigen.
  • Example 1 In-vitro T-cell killing analysis of T-cells according to the present invention transduced with chimeric CD 95 receptor polypeptides and an engineered T-cell receptor
  • chimeric CD 95 receptor constructs In order to test the T-cells expressing chimeric CD 95 receptor constructs together with an engineered T-cell receptor described herein for suitability in adoptive T- cell therapy (ACT), and/or for increasing cytotoxicity of the generated T-cells that express the chimeric CD 95 switch receptors and the engineered T-cell receptor, chimeric CD 95 receptor constructs have been used to transduce CD8 T-cells together with a HLA-I restricted TCR raised against MAGE-A1. Purified transduced T-cells were used in an in- vitro T-cell killing assay with NCI-H2030 FASL-expressing cells and HeLa FASL- expressing cells, respectively, for evaluating cytotoxicity of the transduced T-cells.
  • ACT adoptive T- cell therapy
  • EC relates to the origin of the extracellular domain of the chimeric receptor.
  • TM relates to the origin of the transmembrane domain of the chimeric receptor, and
  • CYP relates to the origin of the cytoplasmic domain of the generated construct.
  • Table 3 summarizes further chimeric CD 95 receptor constructs as used for the T-cell killing assay shown in Fig. 4, and chimeric CD8 co-receptor type as used in the T-cell killing assay shown in Fig. 4 [00174] Table 3
  • the expression “EC” relates to the origin of the extracellular domain of the chimeric receptor.
  • “TM” relates to the origin of the transmembrane domain of the chimeric receptor, and
  • CYP relates to the origin of the cytoplasmic domain of the generated construct, and
  • Co-receptor type relates to the type of the CD8-coreceptor that is co-transduced into the T-cells, which is - in all constructs according to Table 3, p638, thus encoding a chimeric CD8 co-receptor with costimulatory domain of CD30 (CD30 motif) and CD40 both fused to the cytoplasmic domain of CD4.
  • PBMCs from a healthy donor buffy coat were isolated by density gradient centrifugation with Lymphoprep.
  • Purified polyclonal CD8 T-cells were obtained by negative selection with anti-CD4 microbeads for depleting C4 population.
  • CD3 T-cells were activated using TransAct in presence of IL-7/IL-15.
  • CD8 T-cells were separately transduced with either HLA-I restricted TCR raised against MAGE-A1 (MAGE-A1_TCR) alone, or together with different versions of the SWITCH receptors.
  • H LA-1 restricted TCR raised against MAGE-A1 MAGE-A1_TCR
  • Transduced CD8 T-cells were further expanded, and at Day 9 the transduced fraction was positively selected using CD34 microbeads.
  • Purified transduced T-cells were cultured for further expansion and were harvested and cryopreserved at Day 10.
  • T-cell characterization was based on transgene expression levels using FACS and killing assay.
  • the in-vitro T-cell killing assay was performed according to the method described e.g. by Kalbasi, A., Siurala, M., Su, L.L. et al., “Potentiating adoptive cell therapy using synthetic IL-9 receptors”; Nature 607, 360-365 (2022).
  • the human TCR T-cell repetitive killing assay was conducted using IncuCyte Live Cell Analysis. NCIH2030 1x10 4 tumor cells were plated per well in 96-well plates.
  • the in-vitro T-cell killing assay was performed according to the method described e.g. by Kalbasi, A., Siurala, M., Su, L.L. et al., “Potentiating adoptive cell therapy using synthetic IL-9 receptors”; Nature 607, 360-365 (2022).
  • the human TCR T-cell repetitive killing assay was conducted using IncuCyte Live Cell Analysis. HeLa 1x10 4 tumor cells were plated per well in 96-well plates.
  • Untransduced (mock), or transduced human T-cells were added in triplicates at 1 to 2 E:T ratio.
  • tumor cells HeLa 1 x104
  • tumor cells were added, respectively, to each well after cancer cells from the previous stimulation are killed, typically 50h to 100h from the beginning of the experiment.
  • CD8 T cells were separately transduced with either HLA-I restricted TCR raised against MAGE-A1 (MAGE-A1_TCR) alone, or together with different versions of the SWITCH receptors. Where indicated (results in Fig. 4), a chimeric CD8 Co-receptor was co-transduced (CoR).
  • the chimeric CD8 Co-receptor used in the experiments is the Chimeric CD-8 Co-receptor polypeptide (pTK-0638) having an amino acid sequence as set forth in SeqID No. 50.
  • Extracellular surface staining was performed for 30 minutes at 4°C in flow cytometry FACS buffer (BD Bioscience).
  • the following antibodies were used: from BioLegend: CD8a (clone HIT8a); from Invitrogen: CD34 (clone QBEND10), CD34 (clone 4H11); from Miltenyi Biotec: CD8a (clone REA734), CD95 (clone DX2), from Beckman Coulter: TCRBV3S1 Vp3.
  • PE-conjugated HLA-A*02:01 specific MAGE-A1 MHC tetramer (KVLEYVIKV) (SEQ ID NO: 52) (TB-M070-1) was added together with cell surface staining antibodies.
  • Zombie YellowTM Fixable Viability Kit was used to discriminate between live and dead cells.
  • the expression of the chimeric CD 95 receptor has been determined for CD8 cells transduced with different chimeric CD 95 receptors as herein provided.
  • Fig. 2 shows the results of the killing assay with the chimeric CD 95 receptors in HeLa cells
  • Fig. 3 shows the result of the cell killing assay with the chimeric CD 95 receptors in NCIH2030 cells.
  • “Mock” relates to mock-transduced T-cell fraction
  • “MAGE_TCR” relates to CD8 T-cell fraction transduced with HLA-I restricted TCR raised against MAGE-A1 (MAGE-A1_TCR)
  • “MAGE-A1_TCR-SwR_CD40” relates to CD8 T-cell fraction transduced with HLA-I restricted TCR raised against MAGE-A1 (MAGE-A1_TCR) together with a chimeric CD 95 receptor comprising CD 40 cytoplasmic domain
  • “MAGE-A1_TCR- SwR_CD40L” relates to CD8 T-cell fraction transduced with HLA-I restricted TCR raised against MAGE-A1 (MAGE-A1_TCR) together with a chimeric CD 95 receptor comprising CD 40L cytoplasmic domain
  • “MAGE-A1_TCR-SwR_CD27” relates to CD8 T-cell fraction transduced with HLA-I restricted TCR raised against
  • Fig. 4 shows the results of a long term killing assay, wherein T-cells were transduced with either Mock, or a Mage-A1 TCR (MAGE A1 TCR), or a Mage-A1 TCR with a wildtype CD8 co-receptor (Mage A1 TCR WT_CoR), or a Mage-A1 TCR with a chimeric CD8 co-receptor (Mage A1 TCR ESC_CoR), or a Mage-A1 TCR with a chimeric CD8 co-receptor and a respective one of the chimeric CD 95 receptor constructs as herein described (Mage A1 TCR ESC_CoR FAS CD40, Mage A1 TCR ESC_CoR FAS CD30, Mage A1 TCR ESC_CoR FAS 0X40, Mage A1 TCR ESC_CoR FAS CD2, Mage A1 TCR ESC_CoR FAS CD27, Mage A1 TCR ESC_Co
  • CD8 cells transduced with vectors comprising nucleic acids encoding for different chimeric CD 95 receptors as herein provided have been checked for expression of the chimeric CD 95 receptor.
  • Fig. 1 only the chimeric CD 95 receptors comprising cytoplasmic domains of 41 BB, GITR and CD40L, respectively, show comparably low percentage of Fas-high population, whereas all other tested chimeric CD 95 receptors show high percentages of Fas high population.
  • T-cells co-transduced with an engineered HLA-I restricted TCR raised against MAGE-A1 together with a chimeric CD 95 receptor as herein provided, and together with a chimeric CD8 Co-receptor results in an increased killing activity of the engineered T-cells compared with mock transduced T-cells and/or T-cells only transduced with the HLA-I restricted TCR raised against MAGE-A1 , as visible in NCIH2030 cells.
  • the results described above demonstrate - in principle - suitability of the T- cells comprising both a chimeric CD 95 receptor polypeptides as well as an engineered T- cell receptor as herewith provided for improving adoptive cell therapy (ACT).
  • the chimeric CD 95 receptor polypeptides of the present invention in combination with the engineered T-cell receptor, may be functional in providing improved resistance to the T-cell in immunosuppressive tumor microenvironment, in preventing T-cell exhaustion and/or depletion through apoptosis; and in stimulating T-cell proliferation and functional activity, such as increased cytotoxicity.
  • fusion of at least one cytoplasmic costimulatory motif, costimulatory domain, or costimulatory polypeptide region e.g. of a tumor necrosis factor receptor superfamily protein comprising CD40, CD40L, CD27, HVEM, GITR, CD30, 0X40, and/or LTBR, an immunoglobulin superfamily (IgSF) protein, a Toll-like-receptor, and/or an IL6-receptor family protein to a chimeric CD 95 receptor that comprises the CD 95 ligand binding domain
  • IgSF immunoglobulin superfamily

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention se rapporte, entre autres, à un lymphocyte T exprimant un récepteur CD 95 chimérique comprenant un polypeptide, ledit polypeptide comprenant au moins une région polypeptidique dérivée de CD 95 présentant au moins 60 % d'identité de séquence avec un domaine polypeptidique, une région polypeptidique ou un motif polypeptidique d'un récepteur CD 95 humain de type sauvage, ladite région polypeptidique de CD 95 humain comprenant un domaine de liaison de ligand extracellulaire CD 95; ledit polypeptide comprenant en outre au moins un domaine polypeptidique cytoplasmique co-stimulateur non CD 95, une région ou un motif d'une protéine de la superfamille du récepteur du facteur de nécrose tumorale comprenant CD40, CD40L, CD27, HVEM, GITR, CD30, OX40 et/ou LTBR, une protéine de la superfamille des immunoglobulines (IgSF), un récepteur de type Toll et/ou une protéine de la famille des récepteurs IL6; le lymphocyte T exprimant en outre un récepteur de lymphocytes T modifié. La présente invention se rapporte également à un vecteur comprenant des acides nucléiques codant pour le récepteur CD 95 et le récepteur de lymphocytes T modifiés, ainsi qu'à un kit pour préparer les lymphocytes T selon la présente invention, et à une composition pharmaceutique comprenant les lymphocytes T. L'invention se rapporte également à un procédé permettant de préparer un lymphocyte T pour l'immunothérapie, et à une méthode permettant de traiter un patient atteint d'une maladie comprenant l'administration de la composition pharmaceutique.
PCT/EP2024/073652 2023-08-25 2024-08-23 Récepteur de commutateur cd 95 humain chimérique, lymphocytes t exprimant un tel récepteur conjointement avec un récepteur de lymphocytes t modifié, vecteurs respectifs, kits, compositions pharmaceutiques et méthodes pour traiter un patient présentant une maladie Pending WO2025045752A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23193416 2023-08-25
EP23193416.7 2023-08-25

Publications (1)

Publication Number Publication Date
WO2025045752A1 true WO2025045752A1 (fr) 2025-03-06

Family

ID=87845770

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/073652 Pending WO2025045752A1 (fr) 2023-08-25 2024-08-23 Récepteur de commutateur cd 95 humain chimérique, lymphocytes t exprimant un tel récepteur conjointement avec un récepteur de lymphocytes t modifié, vecteurs respectifs, kits, compositions pharmaceutiques et méthodes pour traiter un patient présentant une maladie

Country Status (1)

Country Link
WO (1) WO2025045752A1 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014118236A2 (fr) 2013-01-29 2014-08-07 Max-Delbrück-Centrum Für Moledulare Medizin (Mdc) Berlin-Buch Constructions à avidité élevée de reconnaissance d'antigènes
WO2017044672A1 (fr) * 2015-09-11 2017-03-16 Agenus Inc Cellules hôtes génétiquement modifiées et leurs procédés d'utilisation
WO2018183551A1 (fr) * 2017-03-28 2018-10-04 Cell Design Labs, Inc. Polypeptides chimériques et procédés de modification de leur localisation dans la membrane cellulaire
WO2021051195A1 (fr) * 2019-09-16 2021-03-25 Mcmaster University Récepteurs de costimulation chimériques et procédés et utilisations de ceux-ci
US11304978B2 (en) * 2019-05-01 2022-04-19 Pact Pharma, Inc. Compositions and methods for the treatment of cancer using a CD8 engineered T cell therapy
WO2022132836A2 (fr) * 2020-12-14 2022-06-23 Fred Hutchinson Cancer Research Center Compositions et méthodes pour l'immunothérapie cellulaire
WO2023083864A1 (fr) 2021-11-09 2023-05-19 T-Knife Gmbh Méthodes de sélection d'un patient pour le traitement d'une tumeur solide positive pour mage-a1, de prédiction de la sensibilité d'un patient diagnostiqué comme atteint d'une tumeur solide positive pour mage-a1 au traitement de cette tumeur et de traitement d'un patient diagnostiqué comme atteint d'une telle tumeur solide positive pour mage-a1, ainsi que des compositions pharmaceutiques et des kits de diagnostic correspondants
EP4219554A1 (fr) * 2020-11-03 2023-08-02 Bioheng Therapeutics Limited Anticorps humanisé ciblant cd7 et son utilisation

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014118236A2 (fr) 2013-01-29 2014-08-07 Max-Delbrück-Centrum Für Moledulare Medizin (Mdc) Berlin-Buch Constructions à avidité élevée de reconnaissance d'antigènes
WO2017044672A1 (fr) * 2015-09-11 2017-03-16 Agenus Inc Cellules hôtes génétiquement modifiées et leurs procédés d'utilisation
WO2018183551A1 (fr) * 2017-03-28 2018-10-04 Cell Design Labs, Inc. Polypeptides chimériques et procédés de modification de leur localisation dans la membrane cellulaire
US11304978B2 (en) * 2019-05-01 2022-04-19 Pact Pharma, Inc. Compositions and methods for the treatment of cancer using a CD8 engineered T cell therapy
WO2021051195A1 (fr) * 2019-09-16 2021-03-25 Mcmaster University Récepteurs de costimulation chimériques et procédés et utilisations de ceux-ci
EP4219554A1 (fr) * 2020-11-03 2023-08-02 Bioheng Therapeutics Limited Anticorps humanisé ciblant cd7 et son utilisation
WO2022132836A2 (fr) * 2020-12-14 2022-06-23 Fred Hutchinson Cancer Research Center Compositions et méthodes pour l'immunothérapie cellulaire
WO2023083864A1 (fr) 2021-11-09 2023-05-19 T-Knife Gmbh Méthodes de sélection d'un patient pour le traitement d'une tumeur solide positive pour mage-a1, de prédiction de la sensibilité d'un patient diagnostiqué comme atteint d'une tumeur solide positive pour mage-a1 au traitement de cette tumeur et de traitement d'un patient diagnostiqué comme atteint d'une telle tumeur solide positive pour mage-a1, ainsi que des compositions pharmaceutiques et des kits de diagnostic correspondants

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"Molecular Cloning: A Laboratory Manual", vol. 1-3, 2001, COLD SPRING HARBOR LABORATORY PRESS
"UniProtKB", Database accession no. P10966
ALTSCHUL, S. F. ET AL., NUCL. ACIDS RES., vol. 25, 1997, pages 3389 - 3402
BELL ET AL., EXPERIMENTAL BIOLOGY AND MEDICINE, vol. 235, 2010, pages 1269 - 1276
HOOGI SHIRAN ET AL: "A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 7, no. 1, 9 September 2019 (2019-09-09), XP093054400, Retrieved from the Internet <URL:http://link.springer.com/article/10.1186/s40425-019-0721-y/fulltext.html> DOI: 10.1186/s40425-019-0721-y *
KALBASI, A.SIURALA, M.SU, L.L. ET AL.: "Potentiating adoptive cell therapy using synthetic IL-9 receptors", NATURE, vol. 607, 2022, pages 360 - 365, XP037900195, DOI: 10.1038/s41586-022-04801-2
MERTEN ET AL., J. VIROL., vol. 79, 2005, pages 834 - 840
RAMAMOORTHNARVEKAR: "Non Viral Vectors in Gene Therapy- An Overview", JCLINDIAGN RES, vol. 9, no. 1, 2015, pages 01 - 06
WANG ET AL., J. VIROL., vol. 81, 2007, pages 10869 - 10878

Similar Documents

Publication Publication Date Title
US12351617B2 (en) Immune cells comprising truncated NKG2D chimeric receptors
US12371489B2 (en) Car based immunotherapy
US12258381B2 (en) Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
CN109306016B (zh) 共表达细胞因子il-7的nkg2d-car-t细胞及其用途
CN108004259B (zh) 靶向b细胞成熟抗原的嵌合抗原受体及其用途
KR20140127829A (ko) 2세대 키메라 항원 수용체에서 cd2 시그널링 도메인의 용도
WO2017172952A1 (fr) Cellules car-t cd19 marquées par flag
JP6762485B2 (ja) 抗グリピカン−１−免疫抗原受容体
WO2018068766A1 (fr) Récepteur antigénique chimérique ciblant le cd19, son procédé de préparation et son application
WO2021188454A1 (fr) Compositions de cellules modifiées et leurs procédés d&#39;utilisation
CN115477704B (zh) 一种基于lox1构建的嵌合抗原受体免疫细胞制备及其应用
JP2022542051A (ja) 養子免疫療法のための組成物および方法
EP4663663A1 (fr) Utilisation de la protéine naturelle tsh comme site de liaison à l&#39;antigène dans la construction de cellules car-t ciblant tshr
WO2025045752A1 (fr) Récepteur de commutateur cd 95 humain chimérique, lymphocytes t exprimant un tel récepteur conjointement avec un récepteur de lymphocytes t modifié, vecteurs respectifs, kits, compositions pharmaceutiques et méthodes pour traiter un patient présentant une maladie
CN115806626B (zh) 一种基于csf1的嵌合抗原受体免疫细胞制备及其应用
CN115819614B (zh) 一种基于il34的嵌合抗原受体免疫细胞制备及其应用
WO2025190565A1 (fr) Récepteur de protéine 1 de mort cellulaire programmée chimérique
WO2025191067A1 (fr) Récepteur transmembranaire chimérique comprenant au moins immunorécepteur de lymphocytes t avec une region polypeptidique des domaines ig et itim (tigit), des lymphocytes t exprimant le récepteur de commutateur tigit humain chimérique, des vecteurs avec des acides nucléiques codant pour le récepteur tigit, des kits pour préparer les lymphocytes t, ainsi que des compositions pharmaceutiques correspondantes et des méthodes pour traiter un patient ayant une maladie et pour augmenter la cytotoxicité d&#39;un lymphocyte t dans une thérapie cellulaire adoptive
WO2025027088A1 (fr) Co-récepteur cd8 humain chimérique amélioré, acide nucléique codant pour le co-récepteur cd8 humain chimérique amélioré, vecteurs correspondants, lymphocytes t isolés transduits avec l&#39;acide nucléique ou vecteurs correspondants et kits pour les préparer, compositions pharmaceutiques correspondantes et méthodes de traitement d&#39;un patient atteint d&#39;une maladie
CN115960256A (zh) 一种长效的嵌合抗原受体、载体及其构建方法和应用
WO2025027087A1 (fr) Co-récepteur cd8 humain chimérique, acide nucléique codant pour le co-récepteur cd8 humain chimérique, vecteurs correspondants, lymphocytes t isolés transduits avec l&#39;acide nucléique ou vecteurs correspondants et kits pour les préparer, ainsi que compositions pharmaceutiques correspondantes et méthodes de traitement d&#39;un patient ayant une maladie
TW202237825A (zh) 針對同種異體細胞療法的通用嵌合抗原受體表現之免疫細胞
US20250388645A1 (en) Immune Cells Comprising Truncated NKG2D Chimeric Receptors
WO2024179518A1 (fr) Car-t à double cible ayant un domaine itam optimisé et molécules co-stimulatrices double cd28 et 4-1bb
HK1234091A1 (en) Trifunctional t cell-antigen coupler and methods and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24772218

Country of ref document: EP

Kind code of ref document: A1